Intravenous immunoglobulin as a therapy for autoimmune conditions.

Autor: Danieli MG; SOS Immunologia delle Malattie Rare e dei Trapianti. AOU delle Marche & Dipartimento di Scienze Cliniche e Molecolari, Università Politecnica delle Marche, via Tronto 10/A, 60126 Torrette di Ancona, Italy; Postgraduate School of Allergy and Clinical Immunology, Università Politecnica delle Marche, via Tronto 10/A, 60126 Ancona, Italy. Electronic address: m.g.danieli@univpm.it., Antonelli E; Postgraduate School of Internal Medicine, Università Politecnica delle Marche, 60126 Ancona, Italy., Gammeri L; Postgraduate School of Allergy and Clinical Immunology, University of Messina, 98121 Messina, Italy., Longhi E; Postgraduate School in Clinical Pathology and Clinical Biochemistry, Università Politecnica delle Marche, via Tronto 10/A, 60126 Ancona, Italy. Electronic address: eleonora.longhi@studio.unibo.it., Cozzi MF; Postgraduate School of Internal Medicine, Università Politecnica delle Marche, 60126 Ancona, Italy., Palmeri D; Postgraduate School of Allergy and Clinical Immunology, Università Politecnica delle Marche, via Tronto 10/A, 60126 Ancona, Italy., Gangemi S; Operative Unit of Allergy and Clinical Immunology, Department of Clinical and Experimental Medicine, University of Messina, Via Consolare Valeria 1, 98125 Messina, Italy. Electronic address: sebastiano.gangemi@unime.it., Shoenfeld Y; Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Ramat Gan 52621, Israel; Reichman University, Herzelia 46101, Israel. Electronic address: yehuda.shoenfeld@sheba.health.gov.il.
Jazyk: angličtina
Zdroj: Autoimmunity reviews [Autoimmun Rev] 2025 Jan 03; Vol. 24 (1), pp. 103710. Date of Electronic Publication: 2024 Nov 24.
DOI: 10.1016/j.autrev.2024.103710
Abstrakt: Intravenous immunoglobulin (IVIg) is a medical preparation used as replacement therapy for patients with immunodeficiencies. Over time, IVIg's anti-inflammatory and immunomodulatory effects have been recognized, which have led to the approval of this therapy in the treatment of various pathologies, such as Kawasaki disease, immune thrombocytopenia, and Guillain-Barré syndrome. There are numerous studies in the literature regarding the off-label use of IVIg in the treatment of autoimmune diseases (e.g. myositis and vasculitis), and hematological disorders. Since the role of immunoglobulins in fields other than replacement therapy is now consolidated, in this study we carried out a review of the literature to evaluate the main uses of IVIg therapy. We have focused our attention on the treatment of autoimmune, neurological, hematological, dermatological and pediatric diseases. Furthermore, our analysis of the literature also extended to the potential use of IVIg as an adjuvant treatment of long COVID-19. From our analysis, we found consistent data about IVIg's effectiveness in treating numerous clinical conditions. Treatment with IVIg represents a second-line approach or a valid adjuvant to standard therapies capable of positively influencing the clinical course of many pathologies and reducing or avoiding side effects of standard therapies, with a good safety profile.
Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests. Maria Giovanna Danieli and Yehuda Shoenfeld are serving in the Editorial Board of Autoimmunity Reviews. The other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. The other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: